RXRX241018P11000
- 4.58
- 0.000.00%
Recursion Pharmaceuticals Newsroom
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals' Groundbreaking Cancer Drug Enters Clinical Trials
Express News | Recursion Pharmaceuticals Shares up 2.8% Premarket on Getting US FDA Clearance for Early-Stage Cancer Drug Trial
Express News | Recursion Pharmaceuticals Inc - to Initiate Phase 1/2 Dosing of REC-1245 in Q4 2024
Express News | Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals Director Sells Over $78k in Company Stock
Angle PLC Announces Agreement With Recursion Pharmaceuticals
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Morgan Stanley analyst Vikram Purohit maintains $Recursion Pharmaceuticals(RXRX.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
Needham analyst Gil Blum maintains $Recursion Pharmaceuticals(RXRX.US)$ with a buy rating, and adjusts the target price from $16 to $11.According to TipRanks data, the analyst has a success rate of 38
Cathie Wood's ARK Sells CareDx, Buys Recursion Pharmaceuticals Stock
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
On Sep 04, major Wall Street analysts update their ratings for $Recursion Pharmaceuticals(RXRX.US)$, with price targets ranging from $8 to $14.Morgan Stanley analyst Vikram Purohit maintains with a
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns